Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - GEN
LB  - 1.
AU  - Cancer Research UK
TI  - Myeloma
PB  - CancerHelp UK
PY  - 2009
UR  - www.cancerhelp.org.uk/type/myeloma/about/what-is-myeloma
Y2  - 28 May 2010
ER  - 
TY  - CHAP
LB  - 2.
AU  - Munshi, NC
AU  - Longo, DL
AU  - Anderson, KC
TI  - Plasma cell disorders
A2  - Fauci, AS
A2  - Kasper, DL
A2  - Longo, DL
A2  - Braunwald, E
A2  - Hauser, SL
A2  - Jameson, JL
T2  - Harrison’s principles of internal medicine
ET  - 17th
CY  - London
PB  - McGraw-Hill
PY  - 2008
ER  - 
TY  - JOUR
LB  - 3.
AU  - Ashcroft, AJ
AU  - Davies, FE
AU  - Morgan, GJ
TI  - Aetiology of bone disease and the role of bisphosphonates in multiple myeloma
J2  - Lancet Oncol
PY  - 2003
VL  - 4
SP  - 284
EP  - 292
ER  - 
TY  - CHAP
LB  - 4.
AU  - Dispenzieri, A
AU  - Lacy, MQ
AU  - Greipp, PR
TI  - Multiple myeloma
A2  - Greer, JP
A2  - Foerster, J
A2  - Rodgers, GM
A2  - Paraskevas, F
A2  - Glader, B
A2  - Arber, DA
T2  - Wintrobe’s clinical hematology
CY  - Philadelphia, PA
PB  - Lippincott, Williams & Wilkins
PY  - 2009
ER  - 
TY  - CHAP
LB  - 5.
AU  - Munshi, N
AU  - Anderson, KC
TI  - Plasma cell neoplasms
A2  - Govindam, R
T2  - Devita, Hellman & Rosenberg’s cancer: principles & practice of oncology.
CY  - Philadelphia, PA
PB  - Lippincott, Williams & Wilkins
PY  - 2009
ER  - 
TY  - GEN
LB  - 6.
AU  - World Health Organization
TI  - International classification of diseases 10 (ICD-10)
CY  - Geneva
PB  - WHO
PY  - 2004
ER  - 
TY  - JOUR
LB  - 7.
AU  - Gonzalez, D
AU  - van der Burg, M
AU  - Garcia-Sanz, R
AU  - Fenton, JA
AU  - Langerak, AW
AU  - Gonzalez, M
TI  - Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma
J2  - Blood
PY  - 2007
VL  - 110
SP  - 3112
EP  - 3121
ER  - 
TY  - JOUR
LB  - 8.
AU  - Morgan, GJ
AU  - Davies, FE
AU  - Linet, M
TI  - Myeloma aetiology and epidemiology
J2  - Biomed Pharmacother
PY  - 2002
VL  - 56
SP  - 223
EP  - 234
ER  - 
TY  - JOUR
LB  - 9.
AU  - Fonseca, R
AU  - Barlogie, B
AU  - Bataille, R
AU  - Bastard, C
AU  - Bergsagel, PL
AU  - Chesi, M
TI  - Genetics and cytogenetics of multiple myeloma: a workshop report
J2  - Cancer Res
PY  - 2004
VL  - 64
SP  - 1546
EP  - 1558
ER  - 
TY  - JOUR
LB  - 10.
AU  - Dispenzieri, A
AU  - Rajkumar, SV
AU  - Gertz, MA
AU  - Fonseca, R
AU  - Lacy, MQ
AU  - Bergsagel, PL
TI  - Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and riskadapted therapy (mSMART): consensus statement
J2  - Mayo Clin Proc
PY  - 2007
VL  - 82
SP  - 323
EP  - 341
ER  - 
TY  - EDBOOK
LB  - 11.
AU  - Quinn, M
AU  - Wood, H
AU  - Cooper, N
AU  - Rowan, S
TI  - Cancer atlas of the United Kingdom and Ireland 1991–2000
CY  - Gosport
PB  - Palgrave Macmillan
PY  - 2005
ER  - 
TY  - JOUR
LB  - 12.
AU  - Zangari, M
AU  - van Rhee, F
AU  - Anaissie, E
AU  - Pineda-Roman, M
AU  - Haessler, J
AU  - Crowley, J
TI  - Eightyear median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1
J2  - Br J Haematol
PY  - 2008
VL  - 141
SP  - 433
EP  - 444
ER  - 
TY  - GEN
LB  - 13.
AU  - Office for National Statistics (ONS)
TI  - Cancer statistics registrations. Registrations of cancer diagnosed in 2007, England
CY  - London
PB  - ONS
PY  - 2010
ER  - 
TY  - GEN
LB  - 14.
AU  - Office for National Statistics
TI  - Cancer incidence and mortality in the United Kingdom and constituent countries, 2004–06
CY  - Newport
PB  - Office for National Statistics
PY  - 2009
ER  - 
TY  - ELEC
LB  - 15.
AU  - National Cancer Institute
TI  - SEER cancer statistics review, 1975–2006
UR  - http://seer.cancer.gov/csr/1975_2006/
PY  - 2009
ER  - 
TY  - BOOK
LB  - 16.
TI  - Statistical Information Team
PB  - Cancer Research UK
PY  - 2009
ER  - 
TY  - ELEC
LB  - 17.
AU  - NHS Choices
TI  - Multiple myeloma
UR  - www.nhs.uk/Conditions/Multiple-myeloma/Pages/
M1  - 23 November 2009
ER  - 
TY  - JOUR
LB  - 18.
AU  - Kristinsson, SY
AU  - Goldin, LR
AU  - Björkholm, M
AU  - Koshiol, J
AU  - Turesson, I
AU  - Landren, O
TI  - Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies
J2  - Haematologica
PY  - 2009
VL  - 94
SP  - 1581
EP  - 1589
ER  - 
TY  - JOUR
LB  - 19.
AU  - Durie, BG
AU  - Salmon, SE
TI  - A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
J2  - Cancer
PY  - 1975
VL  - 36
SP  - 842
EP  - 854
ER  - 
TY  - JOUR
LB  - 20.
AU  - Greipp, PR
AU  - San, MJ
AU  - Durie, BG
AU  - Crowley, JJ
AU  - Barlogie, B
AU  - Blade, J
TI  - International staging system for multiple myeloma
J2  - J Clin Oncol
PY  - 2005
VL  - 23
SP  - 3412
EP  - 3420
Clin Oncol23ER  - 
TY  - GEN
LB  - 21.
AU  - National Institute for Health and Clinical Excellence (NICE)
TI  - Bortezomib and thalidomide for the first-line treatment of multiple myeloma
ER  - 
TY  - JOUR
LB  - 22.
AU  - Smith, A
AU  - Wisloff, F
AU  - Samson, D
AU  - UK, MF
AU  - Nordic Myeloma Study Group, British Committee for Standards in Haematology
TI  - Guidelines on the diagnosis and management of multiple myeloma 2005
J2  - Br J Haematol
PY  - 2006
VL  - 132
SP  - 410
EP  - 451
ER  - 
TY  - JOUR
LB  - 23.
AU  - Facon, T
AU  - Mary, JY
AU  - Hulin, C
AU  - Benboubker, L
AU  - Attal, M
AU  - Pegourie, B
TI  - Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial
J2  - Lancet
PY  - 2007
VL  - 370
SP  - 1209
EP  - 1218
ER  - 
TY  - JOUR
LB  - 24.
AU  - Palumbo, A
AU  - Bringhen, S
AU  - Caravita, T
AU  - Merla, E
AU  - Capparella, V
AU  - Callea, V
TI  - Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
J2  - Lancet
PY  - 2006
VL  - 367
SP  - 825
EP  - 831
ER  - 
TY  - JOUR
LB  - 25.
AU  - Palumbo, A
AU  - Bringhen, S
AU  - Liberati, AM
AU  - Caravita, T
AU  - Falcone, A
AU  - Callea, V
TI  - Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
J2  - Blood
PY  - 2008
VL  - 112
SP  - 3107
EP  - 3114
ER  - 
TY  - JOUR
LB  - 26.
AU  - San Miguel, JF
AU  - Schlag, R
AU  - Khuageva, NK
AU  - Dimopoulos, MA
AU  - Shpilberg, O
AU  - Kropff, M
TI  - Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
J2  - N Engl J Med
PY  - 2008
VL  - 359
SP  - 906
EP  - 917
ER  - 
TY  - BOOK
LB  - 27.
AU  - Low, E
TI  - MRC Myeloma IX
CY  - Edinburgh
PB  - Myeloma UK
PY  - 2006
ER  - 
TY  - BOOK
LB  - 28.
AU  - Bird, J
AU  - Owen, R
AU  - d’Sa, S
AU  - Snowden, J
AU  - Littlewood, T
AU  - Pratt, G
TI  - Guidelines on the diagnosis and management of multiple myeloma
CY  - London
PB  - UKMF/BCSH
PY  - 2010
ER  - 
TY  - RPRT
LB  - 29.
AU  - European Medicines Agency (EMEA)
TI  - Summary of Product Characteristics for Thalidomide Celgene
PY  - 2009
CY  - London
PB  - EMEA
ER  - 
TY  - GEN
LB  - 30.
AU  - National Institute for Health and Clinical Excellence (NICE)
TI  - Bortezomib monotherapy for relapsed multiple myeloma (TA 129)
PY  - 2007
ER  - 
TY  - GEN
LB  - 31.
AU  - National Institute for Health and Clinical Excellence (NICE)
TI  - Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy (TA 171)
CY  - London
PB  - NICE
PY  - 2009
ER  - 
TY  - GEN
LB  - 32.
AU  - National Institute for Health and Clinical Excellence (NICE)
TI  - Guidance on cancer services – improving outcomes in haematological cancers – the manual
CY  - London
PB  - NICE
PY  - 2003
ER  - 
TY  - RPRT
LB  - 33.
AU  - European Medicines Agency (EMEA)
TI  - Summary of Product Characteristics for Velcade
CY  - London
PB  - EMEA
PY  - 2009
ER  - 
TY  - RPRT
LB  - 34.
AU  - European Medicines Agency (EMEA)
TI  - Assessment report for Velcade
CY  - London
PB  - EMEA
PY  - 2008
ER  - 
TY  - GEN
LB  - 35.
AU  - British Medical Association and Royal Pharmaceutical Society of Great Britain
TI  - British national formulary.
CY  - London
PB  - BMA and RPS
PY  - 2009
ER  - 
TY  - JOUR
LB  - 36.
AU  - Jenkins, JS
AU  - Sampson, PA
TI  - Conversion of cortisone to cortisol and prednisone to prednisolone
J2  - Br Med J
PY  - 1967
VL  - 2
SP  - 205
EP  - 207
ER  - 
TY  - JOUR
LB  - 37.
AU  - Singhal, S
AU  - Mehta, J
AU  - Desikan, R
AU  - Ayers, D
AU  - Roberson, P
AU  - Eddlemon, P
TI  - Antitumor activity of thalidomide in refractory multiple myeloma
J2  - N Engl J Med
PY  - 1999
VL  - 341
SP  - 1565
EP  - 1571
ER  - 
TY  - JOUR
LB  - 38.
AU  - Teicher, BA
AU  - Ara, G
AU  - Herbst, R
AU  - Palombella, VJ
AU  - Adams, J
TI  - The proteasome inhibitor PS-341 in cancer therapy
J2  - Clin Cancer Res
PY  - 1999
VL  - 5
SP  - 2638
EP  - 2645
ER  - 
TY  - JOUR
LB  - 39.
AU  - Blade, J
AU  - Samson, D
AU  - Reece, D
AU  - Apperley, J
AU  - Bjorkstrand, B
AU  - Gahrton, G
TI  - Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the European Group for Blood and Marrow Transplant
J2  - Br J Haematol
PY  - 1998
VL  - 102
SP  - 1115
EP  - 1123
ER  - 
TY  - GEN
LB  - 40.
AU  - Centre for Reviews and Dissemination (CRD)
TI  - Systematic reviews. CRD’s guidance for undertaking reviews in health care
CY  - York
PB  - University of York
PY  - 2009
ER  - 
TY  - JOUR
LB  - 41.
AU  - Tierney, JF
AU  - Stewart, LA
AU  - Ghersi, D
AU  - Burdett, S
AU  - Sydes, MR
TI  - Practical methods for incorporating summary time-to-event data into meta-analysis
J2  - Trials
PY  - 2007
VL  - 8
SP  - 16
ER  - 
TY  - JOUR
LB  - 42.
AU  - Davies, FE
AU  - Child, J
AU  - Hawkins, K
AU  - Bell, S
AU  - Brown, J
AU  - Drayson, MT
TI  - Newly diagnosed myeloma pateints are at risk of venous thrombotic events: high risk patients need to be identified and receive thromboprophylaxis: the MRC experience
J2  - Blood
PY  - 2004
VL  - 104
SP  - 2395
ER  - 
TY  - JOUR
LB  - 43.
AU  - Morgan, GJ
AU  - Jackson, GH
AU  - Davies, FE
AU  - Drayson, MT
AU  - Owen, RG
AU  - Gregory, WM
TI  - Maintenance thalidomide may improve progression free but not overall survival; results from the Myeloma IX Maintenance Randomisation
J2  - Blood
PY  - 2008
VL  - 112
ER  - 
TY  - JOUR
LB  - 44.
AU  - Morgan, GJ
AU  - Davies, FE
AU  - Owen, RG
AU  - Rawstron, AC
AU  - Bell, S
AU  - Cocks, K
TI  - Thalidomide combinations improve response rates: results from the MRC IX study
J2  - Blood
PY  - 2007
VL  - 110
ER  - 
TY  - CONF
LB  - 45.
AU  - Morgan, GJ
AU  - Davies, FE
AU  - Gregory, WM
AU  - Bell, SE
AU  - Szubert, AJ
AU  - Cocks, K
TI  - The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS
T2  - 51st ASH Annual Meeting and Exposition
CY  - New Orleans, LA
DA  - 5–8 December 2009
ER  - 
TY  - JOUR
LB  - 46.
AU  - Owen, RG
AU  - Rawstron, AC
AU  - Drayson, MT
AU  - Davies, FE
AU  - Jackson, GH
AU  - Ross, FM
TI  - MRD studies in MM: data from the MRC Myeloma IX trial
J2  - Clin Lymphoma Myeloma
PY  - 2009
VL  - 9
SP  - 76
ER  - 
TY  - GEN
LB  - 47.
AU  - Owen, RG
AU  - Child, JA
AU  - Jackson, GH
AU  - Davies, FE
AU  - Drayson, MT
AU  - Ross, FM
TI  - MRC Myeloma IX: Preliminary results from the intensive pathway
PY  - 2009
ER  - 
TY  - GEN
LB  - 48.
AU  - Owen, RG
AU  - Morgan, GJ
AU  - Jackson, H
AU  - Davies, FE
AU  - Drayson, MT
AU  - Ross, FM
TI  - MRC Myeloma IX: Preliminary results from the non-intensive study
PY  - 2009
ER  - 
TY  - GEN
LB  - 49.
AU  - Medical Research Council (MRC) Myeloma IX
TI  - Myelomatosis therapy trial for patients of all age groups
PY  - 2009
ER  - 
TY  - GEN
LB  - 50.
TI  - MRC Myeloma IX trial background information: induction chemotherapy for non-intensive pathway only
PY  - 2009
ER  - 
TY  - GEN
LB  - 51.
TI  - MRC Myeloma IX trial background information: randomisation to maintenance
PY  - 2009
ER  - 
TY  - GEN
LB  - 52.
TI  - MRC Myeloma IX trial baseline data: information on induction chemotherapy for nonintensive pathway only
PY  - 2009
ER  - 
TY  - GEN
LB  - 53.
TI  - Interpretation of the MRC ‘Myeloma IX’ results for the non-transplant (non-intensive) group
PY  - 2009
ER  - 
TY  - GEN
LB  - 54.
TI  - MRC Myeloma IX trial outcomes: results from the non-transplant (non-intensive) group
PY  - 2009
ER  - 
TY  - GEN
LB  - 55.
TI  - Myeloma IX EQ-5D and EORTC QLQ-C30 data summary for NICE
PY  - 2009
ER  - 
TY  - GEN
LB  - 56.
TI  - MRC Myeloma IX trial outcomes: EQ-5D summaries from the non-transplant (nonintensive) group
PY  - 2009
ER  - 
TY  - GEN
LB  - 57.
TI  - MRC Myeloma IX trial outcomes: EORTC QLQ C30 summaries from the non-transplant (non-intensive) group
PY  - 2009
ER  - 
TY  - GEN
LB  - 58.
TI  - MRC Myeloma IX trial outcomes: EORTC QLQ C30 graphs from the non-transplant (nonintensive) group
PY  - 2009
ER  - 
TY  - JOUR
LB  - 59.
AU  - Hulin, C
AU  - Facon, T
AU  - Rodon, P
AU  - Pegourie, B
AU  - Benboubker, L
AU  - Doyen, C
TI  - Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
J2  - J Clin Oncol
PY  - 2009
VL  - 27
SP  - 4848
EP  - 4857
ER  - 
TY  - JOUR
LB  - 60.
AU  - San Miguel, JF
AU  - Schlag, R
AU  - Khuageva, NK
AU  - Dimopoulos, MA
AU  - Shpilberg, O
AU  - Kropff, MH
TI  - Updated follow-up and results of subsequent therapy in the Phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma
J2  - Blood
PY  - 2008
VL  - 112
ER  - 
TY  - CONF
LB  - 61.
AU  - Mateos, M-V
AU  - Richardson, PG
AU  - Schlag, R
AU  - Khuageva, NK
AU  - Dimopoulos, MA
AU  - Shpilberg, O
TI  - Bortezomib plus melphalan–prednisone continues to demonstrate a survival benefit vs melphalan–prednisone in the Phase III VISTA trial in previously untreated multiple myeloma after 3 years’ follow-up and extensive subsequent therapy use
T2  - 51st ASH Annual Meeting and Exposition
CY  - New Orleans, LA
DA  - 5–8 December 2009
ER  - 
TY  - CONF
LB  - 62.
AU  - Dhawan, R
AU  - Robinson, D, Jr
AU  - Meunier, J
AU  - Regnault, A
AU  - Rosa, K
AU  - Cakana, AZ
TI  - Sustained health-related quality of life (HRQoL) improvement in newly diagnosed multiple myeloma patients treated with bortezomib/melphalan/prednisone versus melphalan/prednisone: results from the VISTA trial
T2  - 51st ASH Annual Meeting and Exposition
CY  - New Orleans, LA
DA  - 5–8 December 2009
ER  - 
TY  - JOUR
LB  - 63.
AU  - Gulbrandsen, N
AU  - Waage, A
AU  - Gimsing, P
AU  - Turesson, I
AU  - Juliusson, G
AU  - Abildgaard, N
TI  - A randomised placebo controlled study with melphalan/prednisone vs melphalan/prednisone/ thalidomide: quality of life and toxicity
J2  - Haematologica
PY  - 2008
VL  - 93
ER  - 
TY  - JOUR
LB  - 64.
AU  - Waage, A
AU  - Gimsing, P
AU  - Juliusson, G
AU  - Turesson, I
AU  - Fayers, P
TI  - Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial
J2  - Blood
PY  - 2007
VL  - 110
ER  - 
TY  - JOUR
LB  - 65.
AU  - Wijermans, P
AU  - Schaafsma, M
AU  - van Norden, Y
AU  - Ammerlaan, R
AU  - Wittebol, S
AU  - Sinnige, H
TI  - Melphalan plus prednisone versus melphalan plus prednisone plus thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 Study
J2  - Blood
PY  - 2008
VL  - 112
SP  - 241
EP  - 242
ER  - 
TY  - JOUR
LB  - 66.
AU  - Wijermans, P
AU  - Schaafsma, M
AU  - Van Norden, Y
AU  - Ammerlaan, R
AU  - Sonneveld, P
AU  - Wittebol, S
TI  - Melphalan + prednisone vs melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVON
J2  - Haematologica
PY  - 2008
VL  - 93
SP  - 177
ER  - 
TY  - JOUR
LB  - 67.
AU  - Wijermans, PW
AU  - Zweegman, S
AU  - van Marwijk, KM
AU  - van der Griend, R
AU  - Lokhorst, H
AU  - Schaafsma, M
TI  - MP versus MPT in elderly myeloma patients: the final outcome of the HOVON-49 study
J2  - Clin Lymphoma Myeloma
PY  - 2009
VL  - 9
SP  - S18
ER  - 
TY  - JOUR
LB  - 68.
AU  - Sacchi, S
AU  - Marcheselli, R
AU  - Pozzi, S
AU  - Bari, A
AU  - Ciarcia, O
AU  - Masini, L
TI  - A randomized phase II study (GISL-MM03 Trial) with oral melphalan plus prednisone (MP) versus melphalan, plus prednisone plus thalidomide (MPT) for newly diagnosed elderly patients with multiple myeloma
J2  - Haematologica
PY  - 2009
VL  - 94
SP  - 384
ER  - 
TY  - CONF
LB  - 69.
AU  - Beksac, M
AU  - Haznedar, R
AU  - Firatli-Tuglular, T
AU  - Ozdogu, H
AU  - Aydogdu, I
AU  - Konuk, N
TI  - Addition of thalidomide (T) to oral melphalan/prednisone (MP) in patients with multiple myeloma: initial results of a randomized trial from the Turkish Myeloma Study Group
T2  - 51st ASH Annual Meeting and Exposition
CY  - New Orleans, LA
DA  - 5–8 December 2009
ER  - 
TY  - JOUR
LB  - 70.
AU  - Sampson, FC
AU  - Beard, SM
AU  - Scott, F
AU  - Vandenberghe, E
TI  - Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma
J2  - Br J Haematol
PY  - 2001
VL  - 113
SP  - 1015
EP  - 1019
ER  - 
TY  - JOUR
LB  - 71.
AU  - Cecchi, M
AU  - Caccese, E
AU  - Messori, A
AU  - Orsi, C
AU  - Tendi, E
TI  - Cost-effectiveness of bortezomib in multiple myeloma
J2  - Pharm World Sci
PY  - 2007
VL  - 29
SP  - 485
EP  - 486
ER  - 
TY  - JOUR
LB  - 72.
AU  - Deniz, B
AU  - Facon, T
AU  - Singer, I
AU  - Micallef-Eynaud, P
AU  - Joseph, I
AU  - Shearer, A
TI  - Economic evaluation of thalidomide combined with melphalan and prednisone in previously untreated multiple myeloma in Scotland
J2  - Blood
PY  - 2008
VL  - 112
SP  - 835
ER  - 
TY  - JOUR
LB  - 73.
AU  - Yoong, K
AU  - Attard, C
AU  - Jivraj, F
AU  - Shustik, C
AU  - Reece, D
TI  - Cost effectiveness analysis of bortezomib in previously untreated multiple myeloma patients in Canada
J2  - Value Health
PY  - 2009
VL  - 12
SP  - A272
ER  - 
TY  - JOUR
LB  - 74.
AU  - Joseph, I
AU  - Facon, T
AU  - Lewis, P
AU  - Deniz, HB
AU  - Caro, JJ
TI  - Cost effectiveness of thalidomide combined with melphalan and prednisone in previously untreated myltiple myeloma in Wales
J2  - Value Health
PY  - 2009
VL  - 12
SP  - A271
ER  - 
TY  - JOUR
LB  - 75.
AU  - De Abreu Lourenco, R
AU  - Colman, S
AU  - Lee, C
TI  - Thalidomide plus melphan and prednisone for Australian patients newly diagnosed with multiple myeloma is cost effective when compared with melphalan and prednisone alone
J2  - Value Health
PY  - 2009
VL  - 12
SP  - A381
ER  - 
TY  - CONF
LB  - 76.
AU  - Wang, S
AU  - Huang, H
AU  - Shi, H
AU  - Duh, M
AU  - Chen, K
TI  - The cost effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States
T2  - 51st ASH Annual Meeting and Exposition
CY  - New Orleans, LA
DA  - 5–8 December 2009
ER  - 
TY  - BOOK
LB  - 77.
AU  - Brazier, J
AU  - Ratcliffe, J
AU  - Salomon, JA
AU  - Tsuchiya, A
TI  - Measuring and valuing health benefits for economic evaluation
CY  - Oxford
PB  - Oxford University Press
PY  - 2007
ER  - 
TY  - GEN
LB  - 78.
AU  - National Institute for Health and Clinical Excellence (NICE)
TI  - Guide to the methods of technology appraisal
CY  - London
PB  - NICE
PY  - 2008
ER  - 
TY  - JOUR
LB  - 79.
AU  - Sherman, AC
AU  - Simonton, S
AU  - Latif, U
AU  - Plante, TG
AU  - Anaissie, EJ
TI  - Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation
J2  - Biol Blood Marrow Transplant
PY  - 2009
VL  - 15
SP  - 12
EP  - 20
ER  - 
TY  - JOUR
LB  - 80.
AU  - Lee, SJ
AU  - Richardson, PG
AU  - Sonneveld, P
AU  - Schuster, MW
AU  - Irwin, D
AU  - San Miguel, JF
TI  - Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study
J2  - Br J Haematol
PY  - 2008
VL  - 143
SP  - 511
EP  - 519
ER  - 
TY  - JOUR
LB  - 81.
AU  - Sherman, AC
AU  - Simonton, S
AU  - Latif, U
AU  - Spohn, R
AU  - Tricot, G
TI  - Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation
J2  - Bone Marrow Transplant
PY  - 2004
VL  - 33
SP  - 955
EP  - 962
ER  - 
TY  - JOUR
LB  - 82.
AU  - Gulbrandsen, N
AU  - Wisloff, F
AU  - Brinch, L
AU  - Carlson, K
AU  - Dahl, IM
AU  - Gimsing, P
TI  - Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support
J2  - Med Oncol
PY  - 2001
VL  - 18
SP  - 65
EP  - 77
ER  - 
TY  - JOUR
LB  - 83.
TI  - Multiple myeloma: QALY gains from optimal therapy
J2  - Drugs Ther Perspect
PY  - 2000
VL  - 16
SP  - 12
EP  - 16
ER  - 
TY  - JOUR
LB  - 84.
AU  - Ellis, K
AU  - Smith, AG
TI  - An evaluation of quality of life (QOL) in patients after treatment for multiple myeloma (MM)
J2  - Br J Haematol
PY  - 2005
VL  - 129
SP  - 192
ER  - 
TY  - JOUR
LB  - 85.
AU  - Thomas, ML
TI  - Quality of life in persons with multiple myeloma: a descriptive study
J2  - Blood
PY  - 2001
VL  - 98
SP  - 4971
ER  - 
TY  - JOUR
LB  - 86.
AU  - Deniz, B
AU  - Morgan, G
AU  - Schey, S
AU  - Ishak, J
AU  - Dale, P
AU  - Shearer, A
TI  - Economic evaluation of lenalidomide combined with dexamethasone for the treatment of multiple myeloma in the UK
J2  - Blood
PY  - 2008
VL  - 112
SP  - 836
EP  - 837
ER  - 
TY  - JOUR
LB  - 87.
AU  - Belch, A
AU  - Reece, DE
AU  - Bahlis, NJ
AU  - White, D
AU  - Teixeira, B
AU  - Camacho, F
TI  - Bortezomib [VELCADE (TM)], pegylated liposomal doxorubicin [DOXIL/CAELYX (R)] and dexamethasone in the treatment of previously untreated multiple myeloma patients: impact on quality-of-life
J2  - Blood
PY  - 2007
VL  - 110
SP  - 1058
EP  - 109A
ER  - 
TY  - JOUR
LB  - 88.
AU  - Dhawan, R
AU  - Meunier, J
AU  - Regnault, A
AU  - Robinson, D
AU  - Rosa, K
AU  - Cakana, A
TI  - Impact of complete response on quality of life in newly diagnosed multiple myeloma patients
J2  - Clinical Lymphoma Myeloma
PY  - 2009
VL  - 9
SP  - S58
ER  - 
TY  - JOUR
LB  - 89.
AU  - Meunier, J
AU  - Regnault, A
AU  - Robinson, D
AU  - Rosa, K
AU  - San Miguel, JF
AU  - van de Velde, H
TI  - Impact of tumor response on health-related quality of life (HRQoL) in newly diagnosed multiple myeloma patients treated with velcade/melphalan/prednisone (V-MP): results from the VISTA trial
J2  - Value Health
PY  - 2009
VL  - 12
SP  - A284
ER  - 
TY  - JOUR
LB  - 90.
AU  - Petrucci, MT
AU  - Calabrese, E
AU  - Levi, A
AU  - Federico, V
AU  - Ceccolini, M
AU  - Rizzi, R
TI  - Costs and quality of life of multiple myeloma (MM) in Italy: the Co.Mim Study
J2  - Value Health
PY  - 2009
VL  - 12
SP  - A265
ER  - 
TY  - JOUR
LB  - 91.
AU  - Gulbrandsen, N
AU  - Hjermstad, MJ
AU  - Wisloff, F
AU  - Nordic Myeloma Study Group
TI  - Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences
J2  - Eur J Haematol
PY  - 2004
VL  - 72
SP  - 172
EP  - 180
ER  - 
TY  - JOUR
LB  - 92.
AU  - Strasser-Weippl, K
AU  - Ludwig, H
TI  - Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma
J2  - Eur J Haematol
PY  - 2008
VL  - 81
SP  - 374
EP  - 379
ER  - 
TY  - JOUR
LB  - 93.
AU  - van Agthoven, M
AU  - Segeren, CM
AU  - Buijt, I
AU  - Uyl-de Groot, CA
AU  - van der Holt, B
AU  - Lokhorst, HM
TI  - A cost–utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study
J2  - Eur J Cancer
PY  - 2004
VL  - 40
SP  - 1159
EP  - 1169
ER  - 
TY  - JOUR
LB  - 94.
AU  - Mujica-Mota, R
AU  - Bagust, A
AU  - Haycox, A
AU  - Dhawan, R
AU  - Dubois, D
TI  - Mapping health-related quality of life (HRQOL) measurements into generic utility measures (EQ-5D): a case study with bortezomib (VELCADE)
J2  - Value Health
PY  - 2004
VL  - 7
SP  - 683
ER  - 
TY  - JOUR
LB  - 95.
AU  - Slovacek, L
AU  - Slovackova, B
AU  - Pavlik, V
AU  - Hrstka, Z
AU  - Macingova, Z
AU  - Jebavy, L
TI  - Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis
J2  - Neoplasma
PY  - 2008
VL  - 55
SP  - 350
EP  - 355
ER  - 
TY  - JOUR
LB  - 96.
AU  - Uyl-de Groot, CA
AU  - Buijt, I
AU  - Gloudemans, IJ
AU  - Ossenkoppele, GJ
AU  - Berg, HP
AU  - Huijgens, PC
TI  - Health related quality of life in patients with multiple myeloma undergoing a double transplantation
J2  - Eur J Haematol
PY  - 2005
VL  - 74
SP  - 136
EP  - 143
ER  - 
TY  - JOUR
LB  - 97.
AU  - Gelber, RD
AU  - Goldhirsch, A
AU  - Cole, BF
TI  - Evaluation of effectiveness: Q-TWiST. The International Breast Cancer Study Group
J2  - Cancer Treat Rev
PY  - 1993
VL  - 19
IS  - Suppl. A
SP  - 73
EP  - 84
ER  - 
TY  - JOUR
LB  - 98.
AU  - Philips, Z
AU  - Ginnelly, L
AU  - Sculpher, M
AU  - Claxton, K
AU  - Golder, S
AU  - Riemsma, R
TI  - Review of guidelines for good practice in decision-analytic modelling in health technology assessment
J2  - Health Technol Assess
PY  - 2004
VL  - 8
IS  - 36
ER  - 
TY  - BOOK
LB  - 99.
TI  - Monthly Index of Medical Specialties (MIMS)
PY  - 2009
CY  - London
PB  - Haymarket Medical Media Ltd
ER  - 
TY  - GEN
LB  - 100.
AU  - Department of Health
TI  - NHS reference costs
CY  - London
PB  - DoH
PY  - 2008
ER  - 
TY  - JOUR
LB  - 101.
AU  - Wilson, J
AU  - Yao, GL
AU  - Raftery, J
AU  - Bohlius, J
AU  - Brunskill, S
AU  - Sandercock, J
TI  - A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment
J2  - Health Technol Assess
PY  - 2007
VL  - 11
IS  - 13
ER  - 
TY  - BOOK
LB  - 102.
AU  - Curtis, L
TI  - Unit costs of health and social care
CY  - University of Kent, Canterbury
PB  - Personal Social Services Research Unit
PY  - 2008
ER  - 
TY  - BOOK
LB  - 103.
AU  - Briggs, A
AU  - Sculpher, M
AU  - Claxton, K
TI  - Decision modelling for health economic evaluation
CY  - Oxford
PB  - Oxford University Press
PY  - 2006
ER  - 
TY  - JOUR
LB  - 104.
TI  - Engauge Digitizer – digitizing software
ER  - 
TY  - GEN
LB  - 105.
AU  - Johnson & Johnson Pharmaceutical Research & Development and Millennium: The Takeda Oncology Company
TI  - Clinical Study Report 3: Survival and subsequent therapy update to Clinical Study Report MMY-3002
PY  - 2009
ER  - 
TY  - JOUR
LB  - 106.
AU  - Kontodimopoulos, N
AU  - Aletras, VH
AU  - Paliouras, D
AU  - Niakas, D
TI  - Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments
J2  - Value Health
PY  - 2009
VL  - 12
SP  - 1151
EP  - 1157
ER  - 
TY  - JOUR
LB  - 107.
AU  - McKenzie, L
AU  - van der Pol, M
TI  - Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data
J2  - Value Health
PY  - 2009
VL  - 12
SP  - 167
EP  - 171
ER  - 
TY  - GEN
LB  - 108.
TI  - Contracting Unit, Southampton University Hospital Trust
PY  - 2009
ER  - 
TY  - JOUR
LB  - 109.
AU  - Hicks, LK
AU  - Haynes, AE
AU  - Reece, DE
AU  - Walker, IR
AU  - Herst, JA
AU  - Meyer, RM
TI  - A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma
J2  - Cancer Treat Rev
PY  - 2008
VL  - 34
SP  - 442
EP  - 452
ER  - 
TY  - JOUR
LB  - 110.
AU  - Mehta, J
AU  - Duff, SB
AU  - Gupta, S
TI  - Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma
J2  - Manag Care Interface
PY  - 2004
VL  - 17
SP  - 52
EP  - 61
ER  - 
TY  - JOUR
LB  - 111.
AU  - Kumar, SK
AU  - Therneau, TM
AU  - Gertz, MA
AU  - Lacy, MQ
AU  - Dispenzieri, A
AU  - Rajkumar, SV
TI  - Clinical course of patients with relapsed multiple myeloma
J2  - Mayo Clin Proc
PY  - 2004
VL  - 79
SP  - 867
EP  - 874
ER  - 
TY  - JOUR
LB  - 112.
AU  - Dimopoulos, MA
AU  - Richardson, P
AU  - Schlag, R
AU  - Khuageva, NK
AU  - Shpilberg, O
AU  - Kastritis, E
TI  - Bortezomib-melphalan-prednisone (VMP) in newly diagnosed multiple myeloma patients with impaired renal function: cohort analysis of the Phase III VISTA study
J2  - Blood
PY  - 2008
VL  - 112
SP  - 608
EP  - 609
ER  - 
TY  - JOUR
LB  - 113.
AU  - Harousseau, JL
AU  - Palumbo, A
AU  - Richardson, P
AU  - Schlag, R
AU  - Dimopoulos, MA
AU  - Shpilberg, O
TI  - Superior outcomes associated with complete response: analysis of the Phase III VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
J2  - Blood
PY  - 2008
VL  - 112
ER  - 
TY  - JOUR
LB  - 114.
AU  - San Miguel, J
AU  - Schlag, R
AU  - Khuageva, N
AU  - Dimopoulos, M
AU  - Shpilberg, O
AU  - Kropff, M
TI  - Superior efficacy with bortezomib plus melphalan-prednisone (VMP) versus melphalan-prednisone (MP) alone in previously untreated multiple myeloma (MM): results of the Phase III MMY- 3002 VISTA study
J2  - Haematologica
PY  - 2008
VL  - 93
SP  - 192
ER  - 
TY  - GEN
LB  - 115.
AU  - Janssen–Cilag
TI  - Bortezomib and thalidomide for the first-line treatment of multiple myeloma: bortezomib (Velcade)
CY  - London
PB  - NICE
PY  - 2009
ER  - 
TY  - GEN
LB  - 116.
AU  - Celgene Ltd
TI  - Multiple technology appraisal of bortezomib and thalidomide for the first-line treatment of multiple myeloma
PY  - 2009
ER  - 
TY  - GEN
LB  - 117.
AU  - Celgene Ltd
TI  - A survey of resource utilisation among haematologists in Wales
PY  - 2007
ER  - 
TY  - JOUR
LB  - 118.
AU  - Drummond, MF
AU  - Jefferson, TO
TI  - Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party
J2  - BMJ
PY  - 1996
VL  - 313
SP  - 275
EP  - 283
ER  -